Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Retrieved on:
Thursday, August 11, 2022
FDA, Telephone, Ear, Depression, General Administration of Sport of China, Pain scale, Inflammation, GLOBE, Third Amendment to the Constitution of Pakistan, CT, Conference call, Disease, Incidence, Research, Patient, Sinusitis, COVID-19, Company, Nasal polyp, Nose, Nasal congestion, Polyp (medicine), Reopening the Gates, OPTN, Rhinorrhea, Pressure, GAAP, Headache, NASDAQ, ENT, Exhalation delivery system, MPH, News, Webcast, Investor, Nosebleed, Fluticasone, Pharmaceutical industry, Medical imaging, Health insurance, Online gambling, MD, Conference
Conference call and webcast to be held today at 8:00 a.m. Eastern Time
Key Points:
- Conference call and webcast to be held today at 8:00 a.m. Eastern Time
YARDLEY, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2022, and provided operational updates. - We reported confirmatory, positive topline results from ReOpen2 in June and are further encouraged by the consistency observed in key secondary and pooled results," stated CEO Peter Miller.
- Our current business is performing well, XHANCE net revenue increased 12% in the second quarter of 2022 compared to second quarter 2021 and increased 21% on a year-to-date basis.
- Members of the Companys leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.